[
  {
    "ts": null,
    "headline": "Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?",
    "summary": "DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.",
    "url": "https://finnhub.io/api/news?id=f1671285d6c8f14007909af8e37e3f3893cf929b366b3ba8951eb714cdfffe27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761662160,
      "headline": "Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?",
      "id": 137242486,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.",
      "url": "https://finnhub.io/api/news?id=f1671285d6c8f14007909af8e37e3f3893cf929b366b3ba8951eb714cdfffe27"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Shares Could Be 33% Above Their Intrinsic Value Estimate",
    "summary": "Key Insights The projected fair value for Abbott Laboratories is US$95.46 based on 2 Stage Free Cash Flow to Equity...",
    "url": "https://finnhub.io/api/news?id=86a559a12e90d6f1723e736f56f5df8c1cf2329bf8734edbea61b3f55a599f3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761649253,
      "headline": "Abbott Laboratories (NYSE:ABT) Shares Could Be 33% Above Their Intrinsic Value Estimate",
      "id": 137237851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Key Insights The projected fair value for Abbott Laboratories is US$95.46 based on 2 Stage Free Cash Flow to Equity...",
      "url": "https://finnhub.io/api/news?id=86a559a12e90d6f1723e736f56f5df8c1cf2329bf8734edbea61b3f55a599f3a"
    }
  }
]